학술논문
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Philadelphia chromosome
Philadelphia chromosome
Document Type
Clinical report
Author
Foa, Robin; Bassan, Renato; Vitale, Antonella; Elia, Loredana; Piciocchi, Alfonso; Puzzolo, Maria-Christina; Canichella, Martina; Viero, Piera; Ferrara, Felicetto; Lunghi, Monia; Fabbiano, Francesco; Bonifacio, Massimiliano; Fracchiolla, Nicola; Di Bartolomeo, Paolo; Mancino, Alessandra; De Propris, Maria-Stefania; Vignetti, Marco; Guarini, Anna; Rambaldi, Alessandro; Chiaretti, Sabina
Source
The New England Journal of Medicine. Oct 22, 2020, Vol. 383 Issue 17, p1613, 11 p.
Subject
Language
English
ISSN
0028-4793
Abstract
A phase 2 clinical trial of dasatinib and blinatumomab is conducted in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The treatment was associated with high levels of molecular response and survival among the patients.